COST-EFFECTIVENESS OF GRAZOPREVIR / ELBASVIR IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS

被引：0
|
作者：
Mattingly, T. J., III [1 ]
Slejko, J. F. [1 ]
Mullins, C. D. [1 ]
机构：
[1] Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.396
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PIN47
引用
收藏
页码：A415 / A415
页数：1
相关论文
共 50 条
  • [41] TEMPORAL CHANGES IN COST-EFFECTIVENESS FOR CHRONIC HEPATITIS C VIRUS PHARMACOTHERAPY
    Mattingly, J.
    Love, B. L.
    VALUE IN HEALTH, 2019, 22 : S40 - S40
  • [42] ELBASVIR/GRAZOPREVIR FOR HEPATITIS C VIRUS GENOTYPE 1b PATIENTS RECEIVING HEMODIALYSIS
    Liu, Chen-Hua
    Peng, Cheng-Yuan
    Fang, Yu-Ren
    Yang, Sheng-Shun
    Kao, Wei-Yu
    Lin, Cheng-Kuan
    Liu, Chun-Jen
    Lai, Hsueh-Chou
    Su, Wen-Pang
    Huang, Yi-Jie
    Chang, Chun-Chao
    Su, Tung-Hung
    Chen, Pei-Jer
    Chen, Ding-Shinn
    Kao, Jia-Horng
    HEPATOLOGY, 2019, 70 : 977A - 977A
  • [43] Real-World Cost-Effectiveness Of Elbasvir/Grazoprevir (EBR/GZR) In Treatment-Naive (TN) Patients With Chronic Hepatitis C (CHC) Virus Genotype 1 (GT1) In The United States (US)
    Corman, Shelby L.
    Bacon, Bruce
    Curry, Michael P.
    Dieterich, Douglas T.
    Flamm, Steven L.
    Jiang, Yiling
    Kowdley, Kris V.
    Milligan, Scott
    Nwankwo, Chizoba
    Tsai, Naoky C.
    Younossi, Zobair M.
    Afdhal, Nezam H.
    HEPATOLOGY, 2017, 66 : 621A - 621A
  • [44] Z-PROFILE: Real-world utilization and effectiveness of elbasvir/grazoprevir in adult patients with chronic hepatitis C in Canada
    Conway, B.
    Tam, E.
    Tremblay, J.
    Fraser, C.
    Ramji, A.
    Borgia, S.
    Tsoi, K.
    Yoshida, E.
    Rajendran, B.
    Stewart, K.
    Macphail, G.
    Trottier, B.
    Ghali, P.
    Halsey-Brandt, J.
    Trepanier, J.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S295 - S295
  • [45] Elbasvir/grazoprevir for treatment of chronic hepatitis C virus infection (vol 11, pg 152, 2017)
    Papudesu, Chandana
    Kottilil, Shyamasundaran
    Bagchi, Shashwatee
    HEPATOLOGY INTERNATIONAL, 2017, 11 (03) : 315 - 316
  • [46] Cost-effectiveness of treatment for chronic hepatitis C
    Koff, RS
    JOURNAL OF HEPATOLOGY, 1999, 31 : 255 - 258
  • [47] COST-EFFECTIVENESS OF ELBASVIR/GRAZOPREVIR VERSUS OMBITASVIR/PARITAPREVIR/RITONAVIR PLUS DASABUVIR (3D REGIMEN) FOR TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 1B PATIENTS IN CHINA
    Chen, P. Y.
    Liu, Q.
    Li, H. C.
    Ma, A. X.
    VALUE IN HEALTH, 2018, 21 : S64 - S64
  • [48] The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients
    Linas, Benjamin P.
    Barter, Devra M.
    Leff, Jared A.
    DiLorenzo, Madeline
    Schackman, Bruce R.
    Horsburgh, Charles R.
    Assoumou, Sabrina A.
    Salomon, Joshua A.
    Weinstein, Milton C.
    Kim, Arthur Y.
    Freedberg, Kenneth A.
    AIDS, 2014, 28 (03) : 365 - 376
  • [49] Cost-effectiveness of treatment for chronic hepatitis C infection in patients coinfected with human immunodeficiency virus
    Servoss, JC
    Campos, NG
    Salomon, JA
    Freedberg, KA
    Samet, JH
    Goldie, SJ
    Chung, RT
    HEPATOLOGY, 2005, 42 (04) : 350A - 350A
  • [50] Limited drug-drug interaction of elbasvir/grazoprevir for chronic hepatitis C
    Liu, Chun-Jen
    Tseng, Kuo-Chih
    Lo, Ching-Chu
    Tseng, I-Hao
    Cheng, Pin-Nan
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2020, 119 (05) : 933 - 940
12345